ADMA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
124.4M
+8.6%
114.5M
-17.7%
139.2M
+3.7%
134.2M
+10.0%
122.0M
Cost of Revenue
38.1M
+13.0%
33.7M
-33.0%
50.3M
-14.1%
58.6M
+7.0%
54.8M
Gross Profit
86.3M
+6.8%
80.8M
-9.1%
88.8M
+17.4%
75.6M
+12.5%
67.2M
Operating Expenses
33.8M
+11.1%
30.5M
+16.8%
26.1M
+5.9%
24.6M
+0.8%
24.4M
R&D
6.0M
+131.6%
2.6M
+88.7%
1.4M
-9.9%
1.5M
+48.2%
1.0M
SG&A
26.7M
-0.0%
26.7M
+13.7%
23.5M
+8.0%
21.8M
-2.0%
22.2M
Operating Income
52.4M
+4.3%
50.3M
-19.9%
62.8M
+23.0%
51.0M
+19.2%
42.8M
EBITDA
54.2M
+4.0%
52.1M
-19.5%
64.8M
+22.2%
53.0M
+18.2%
44.9M
Net Income
37.8M
-16.6%
45.3M
-8.2%
49.4M
+35.6%
36.4M
+6.5%
34.2M
EPS (Basic)
$0.17
-10.5%
$0.19
-9.5%
$0.21
+40.0%
$0.15
+7.1%
$0.14
EPS (Diluted)
$0.16
-15.8%
$0.19
-5.0%
$0.20
+33.3%
$0.15
+7.1%
$0.14
Shares (Diluted)
230.3M
-4.0%
240.0M
-0.7%
241.7M
-1.2%
244.7M
-1.6%
248.6M
ADMA Biologics (ADMA) โ€” Financials